KUALA LUMPUR, 6 JULY 2021 – SARS-CoV-2, the etiological agent of the COVID-19 disease, had cause a global pandemic and leaving an enormous impact on every nations worldwide. There is an urgent need for a reliable testing strategy for contact tracing and epidemiological studies, to return to the norm before the pandemic. Besides laboratory PCR testing, antigen and neutralizing antibody assays are also offered as rapid testing in near-patient settings.
Antigen
OJABIO rapid antigen test kits serve as an effective tool to help healthcare personnel to identify infected individuals and isolate possible outbreaks. It detects the presence of the SARS-CoV-2 virus in a sample from the respiratory tract of a person by identifying a nucleoprotein (N-Protein) that is carried by the virus.
OJABIO antigen test kit enables quick decision-making on whether the patients need to be quarantine, hence reducing the risk of the virus to further spread among the community. In addition, it allows for the screening of individuals after the individuals were confirmed to have an exposure to another SARS-CoV-2 infected person or individuals of higher risk, such as the healthcare front liners.
It also allows for decentralized testing at the point of care and helps to expand the range of test into otherwise inaccessible locations. Rapid testing can sometimes be the only available option if PCR testing is not sufficiently available. In addition, OJA antigen test kit is a reliable and easy-to-use visual-read test that does not require laboratory instruments or specialized lab personnel to administer, and it delivers results in 15 minutes.
Neutralizing Antibody
OJABIO rapid COVID-19 Neutralizing Antibody Test kit serves as an effective tool for the detection of SARS-COV-2 neutralizing antibody (NAb), which can be used to determine the immunity status after infection or vaccination.
Neutralizing antibodies can help to inhibit SARS-CoV-2 replication, which means the level of neutralizing antibodies correlates to the immunity of future SARS-CoV-2 infections. Rapid detection of neutralizing antibodies can help with vaccine development, plasma therapy, and immunology studies.
The target applications will be able to detect SARS-CoV-2 neutralizing (virus blocking) antibodies from recovering Covid-19 patients and from vaccinated people as well. The result provides to medical professionals a better grasp of the possibility that the subject has a history of being infected by Covid-19 or the effectiveness of the Covid-19 vaccine on the subject.
General Manager, Medical & Pharmaceutical Research of HWGB Biotech, Dr.Yaman Walid Kassab expressed: “We are elated with the results obtained for Ojabio rapid test Kits. This proofs that it is a reliable test kit of high quality and accuracy. We are obliged to provide only the best solutions to the community and we firmly believe that this will elevate the standards of RTK testing and reduce false results in Covid-19 testing.
***